Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Price: $6.27 -2.18%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ: RNAC) with a Outperform rating and a price target of $39.00.
For an analyst ratings summary and ratings history on Cartesian Therapeutics click here. For more ratings news on Cartesian Therapeutics click here.
Shares of Cartesian Therapeutics closed at $18.26 yesterday.
You May Also Be Interested In
- Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
- HSBC Resumes Fortis Healthcare Ltd (FORH:IN) at Buy
- Freedom Broker Starts Royal Caribbean Cruises (RCL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
